4 TRATAMIENTOS SCLC-ES EN 1.ª LINE EN EUROPA : ATEZOLIZUMAB, DURVALUMAB ,SERPLULIMAB Y TISLELIZUMAB.
LURBINECTEDIN CON IMFORTE TODO EL MUNDO SABE QUE DE APROBARSE NO SERÍA PARA TRATAMIENTO DE PRIMERA LÍNEA .... SINO QUE SERÍA PARA EL MANTENIMIENTO EN EL ENTORNO DE PRIMERA LÍNEA ... O SEA SERÍA UN TRATAMIENTO TRAS LA PRIMERA LÍNEA DE INDUCCIÓN ... PARA QUE LOS PACIENTES NO SE VAYAN A SEGUNDA LÍNEA .
19 octubre 2019
Eribulin . Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment .
Download PDF (3033K)
Pneumothorax has Been Reported as a Pazopanib
-Associated Adverse Event in Patients with Lung Metastases of Soft Tissue Sarcoma (STS).
However, Pneumothorax Triggered by Eribulin Treatment has Mever Been Reported.
We herein report two cases of spontaneous Pneumothorax in Patients with STS treated with Eribulin. Both Patients experienced Pneumothorax accompanied by sudden dyspnea on day 9 or 10 of Eribulin Treatment. These two cases suggest that spontaneous Pneumothorax may occur as an adverse event of Eribulin treatment in such Patients.
We should therefore be alert for the potential development of Pneumothorax during Eribulin Treatment of Patients with STS and Lung Metastases.